Jazz Pharmaceuticals Presents Xywav® Data at Psych Congress 2024
31 Oct 2024 //
PR NEWSWIRE
Enforcement Report - Week of July 24, 2024
24 Jul 2024 //
FDA
Enforcement Report - Week Of June 01, 2022
01 Jun 2022 //
FDA
FDA Grants ODE for Xywav Oral Solution for Idiopathic Hypersomnia in Adults
03 Jan 2022 //
BIOSPACE
Jazz Pharmaceuticals Announces SLEEP Publication of Phase 3 Xywav™
20 Oct 2020 //
PRNEWSWIRE
Jazz Pharmaceuticals to Present New Data on Xywav™ Oral Solution
26 Aug 2020 //
PRNEWSWIRE
Novel naproxen/esomeprazole magnesium compound pellets
02 Mar 2016 //
PHARMA-EXCIPIENTS
Analyst: Vivus generic threats a positive for obesity market
17 Apr 2015 //
ANVISA
Heartburn Drugs Have Serious Side Effects
12 Jan 2015 //
THE SEATTLE TIMES